- Home
- ICLR vs RVMD Comparison
ICLR vs RVMD Comparison
Compare ICLR & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICLR | RVMD |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 15.2B |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ICLR | RVMD |
|---|---|---|
| Price | $185.42 | $120.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 16 |
| Target Price | ★ $201.46 | $81.19 |
| AVG Volume (30 Days) | 944.0K | ★ 4.8M |
| Earning Date | 02-18-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.47 | N/A |
| Revenue | ★ $8,102,602,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.39 | $714.50 |
| P/E Ratio | $24.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $125.10 | $29.17 |
| 52 Week High | $211.00 | $124.49 |
Technical Indicators
Market Signals| Indicator | ICLR | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 84.18 |
| Support Level | $179.54 | $76.28 |
| Resistance Level | $185.99 | $121.62 |
| Average True Range (ATR) | 6.84 | 6.23 |
| MACD | -1.03 | 3.36 |
| Stochastic Oscillator | 41.24 | 91.87 |
Price Performance
Historical ComparisonAbout ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.